Discontinuation of antihyperlipidemic drugs--do rates reported in clinical trials reflect rates in primary care settings?
about
Oral 5-aminosalicylic acid for maintenance of remission in ulcerative colitisOral 5-aminosalicylic acid for induction of remission in ulcerative colitisOral 5-aminosalicylic acid for induction of remission in ulcerative colitisOral 5-aminosalicylic acid for maintenance of remission in ulcerative colitisColesevelam hydrochloride: evidence for its use in the treatment of hypercholesterolemia and type 2 diabetes mellitus with insights into mechanism of actionCholesterol levels and statin use in patients with coronary heart disease treated in primary care settings.Overactive bladder: strategies to ensure treatment compliance and adherenceOptimal lipid modification: the rationale for combination therapyEffect of initial drug choice on persistence with antihypertensive therapy: the importance of actual practice dataAutomated pharmacy databases and behavioral health care quality assurance.Investigating the prevalence, predictors, and prognosis of suboptimal statin use early after a non-ST elevation acute coronary syndrome.Economic evaluation of cholesterol-related interventions in general practice. An appraisal of the evidence.A "hot" topic in dyslipidemia management--"how to beat a flush": optimizing niacin tolerability to promote long-term treatment adherence and coronary disease prevention.The potential applications of Apolipoprotein E in personalized medicineLowering low-density lipoprotein cholesterol levels in patients with type 2 diabetes mellitus.Assessing the adherence to and the therapeutic effectiveness of hypolipidemic agents in a population of patients in Brazil: a retrospective cohort study.Assessing the value of pharmacists' health-systemwide services: clinical pathways and treatment guidelines.An explanatory randomised controlled trial of a nurse-led, consultation-based intervention to support patients with adherence to taking glucose lowering medication for type 2 diabetesCholesterol risk management: a systematic examination of the gap from evidence to practice.Pharmacological effects of HMG CoA reductase inhibitors other than lipoprotein modulation.What proportion of symptomatic side effects in patients taking statins are genuinely caused by the drug? Systematic review of randomized placebo-controlled trials to aid individual patient choice.The impact of non-compliance on the cost-effectiveness of pharmaceuticals: a review of the literature.Applying the results of clinical trials to patients to general practice: perceived problems, strengths, assumptions, and challenges for the future.Effectiveness of treat-to-target strategy for LDL-cholesterol control in type 2 diabetes: post-hoc analysis of data from the MIND.IT study.Impact of statin adherence on cardiovascular disease and mortality outcomes: a systematic reviewMuscarinic receptors in the bladder: from basic research to therapeutics.Non interventional drug studies in oncology: Why we need them?Statin pharmacogenomics: opportunities to improve patient outcomes and healthcare costs with genetic testingPrevention. How much harm? How much benefit? 2. Ten potential pitfalls in determining the clinical significance of benefits.Randomized Trial of a Pharmacist-Delivered Intervention for Improving Lipid-Lowering Medication Adherence among Patients with Coronary Heart DiseaseSuboptimal statin adherence and discontinuation in primary and secondary prevention populations.Development and validation of the hyperlipidemia: attitudes and beliefs in treatment (HABIT) survey for physiciansUndertreatment of hyperlipidemia in the secondary prevention of coronary artery diseaseMeta-analysis: impact of drug class on adherence to antihypertensives.Patient tolerance and acceptance of colesevelam hydrochloride: focus on type-2 diabetes mellitus.Meta-analysis of interventions to improve drug adherence in patients with hyperlipidemia.Adherence to statin treatment and readmission of patients after myocardial infarction: a six year follow up studyInitial therapy, persistence and regimen change in a cohort of newly treated type 2 diabetes patients.High persistence of statin use in a Danish population: compliance study 1993-1998.Who receives lipid-lowering drugs: the effects of comorbidities and patient characteristics on treatment initiation.
P2860
Q24185774-A4A08B3C-E03C-4A6D-BF59-6F91469EAD03Q24185876-47035BCA-BDC3-4D7A-836E-310C075728D4Q24198024-04771689-258A-4754-86A7-4549FA93C9D1Q24198786-65EE31CC-F32E-43D8-BC16-EF0D6A0373C9Q24613405-5C6D3473-02E6-464D-A958-4C86E9242CEDQ25256963-9534DC02-8426-49CF-906D-4A7F58C1DDD2Q26746914-21921D46-EF6B-44C2-A3BE-E1D0EFE74035Q28219266-97E8448C-E73F-4722-AB79-ADFF091E2DA1Q31915694-1A20A16A-7C84-443B-B56E-CA05001BC36BQ33583198-E88F2AE2-DC27-4494-863B-3A0A5E4A4BB8Q33588629-36AA42DA-8BDF-4713-AD29-9C242EF82A85Q33631450-6A467E5F-A2B8-4EEA-8A36-29D74933F3EDQ33765072-BB320129-B734-4D25-86EE-0DA5FB8BF3F8Q33858831-2F1ACBEB-79B0-4E3F-9A84-AA9CA836EE8CQ33890208-153D63D1-70CB-430D-822C-0D5190202583Q33911031-3CE03AA8-0995-4764-ACDC-78C923126916Q34061822-BF3055DB-5592-44A0-972F-08173F0D0B99Q34223066-B4503CB2-9637-4878-A11B-E7EF5A95CE92Q34303364-0221CCE4-C027-4C27-B160-C34FFB4CD050Q34373712-E78CC144-723A-49BA-95A2-ADF0BD07C347Q34409791-0BA6A0DB-7E6F-4065-A9CF-671FB17DBF46Q34464972-604FE889-504B-4EC0-9A6E-6CAAEF89DD18Q34469512-E9105E30-BFEC-43FD-9FAE-3B179D655AAFQ34475329-07FE94FB-F0BF-4FFC-A9FA-6D7F727B367BQ34554376-E854619C-D3E3-4911-9A59-08D533A41E6AQ34564708-16CDEBB9-52BD-4A2C-9986-2D2DA2D449D7Q34595535-148B0D58-F1DF-49F0-8655-638913B67973Q34608646-0E34D0A1-B039-40E9-B827-E36FAB6F1E2BQ34711960-929F8E0F-894E-4EAA-9099-BF1FA18F3D65Q34730092-4AFC4282-06BC-41F3-B787-B977A8969F30Q34732970-1806D5C5-C3E8-4822-89A9-3523DBBDD106Q34742639-7348445B-43A5-4895-BBF4-17D58C74AB91Q34751162-5E8CCB1A-A94B-4BB7-B88A-4EF5460AF5ABQ34887070-AAF1F447-1CA9-49F0-9686-667F75BFFF15Q34976294-EF716BD9-30D6-4189-924C-3808F2BD6BE7Q35043379-F1911428-8A6B-424C-BDA0-32D5998309CBQ35580390-49FF88FD-9C16-4D71-BB25-6C4607CAC20DQ35684836-8087123A-B10D-482E-A6F1-0B27EE6B265EQ35803620-D252634B-5DAF-45D2-9648-CC715B79058EQ35825240-200F370E-3E64-413D-8457-F1A77141A17A
P2860
Discontinuation of antihyperlipidemic drugs--do rates reported in clinical trials reflect rates in primary care settings?
description
1995 nî lūn-bûn
@nan
1995年の論文
@ja
1995年学术文章
@wuu
1995年学术文章
@zh-cn
1995年学术文章
@zh-hans
1995年学术文章
@zh-my
1995年学术文章
@zh-sg
1995年學術文章
@yue
1995年學術文章
@zh
1995年學術文章
@zh-hant
name
Discontinuation of antihyperli ...... ates in primary care settings?
@en
type
label
Discontinuation of antihyperli ...... ates in primary care settings?
@en
prefLabel
Discontinuation of antihyperli ...... ates in primary care settings?
@en
P2093
P1476
Discontinuation of antihyperli ...... ates in primary care settings?
@en
P2093
Andrade SE
Gottlieb LK
Hollenberg NK
Saperia GM
P304
P356
10.1056/NEJM199504273321703
P407
P577
1995-04-01T00:00:00Z